Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.MedImmune will consider buyout offers
Previously, the company had rejected the idea of an acquisition as it wanted to continue with its intended business plan. MedImmune commented that some of its shareholders have
Previously, the company had rejected the idea of an acquisition as it wanted to continue with its intended business plan. MedImmune commented that some of its shareholders have
Chronic idiopathic thrombocytopenic purpura (ITP) is a condition characterized by increased autoimmune platelet destruction and inadequate platelet production. The primary objective of the study is to evaluate the
In December 2003, Array partnered the oncology portion of its MEK program, including its lead compound, ARRY-886, for co-development and commercialization with AstraZeneca. The collaboration included development of
The phase II trial was conducted to assess safety, pharmacodynamics and pharmacokinetics of Hematide in hemodialysis patients with stable baseline hemoglobin (Hgb) levels between 10 and 12.5 g/dL
The reformulation of Suprax allows parents to administer fewer teaspoons per dose of the antibiotic to their children. When using the novel dose, parents would need to administer
The first phase III study demonstrated a statistically significant achievement of all primary and secondary endpoints. Additionally, all primary and secondary endpoints were achieved with statistical significance in
The company initially planned to report first quarter earnings on April 19 but has postponed the announcement to incorporate results of the Aranesp study in small cell lung
Researchers at UT Southwestern Medical Center used a quick-screen technology to isolate 87 genes that seem to affect how sensitive human cancer cells are to certain chemotherapy drugs.
In Friedreich’s ataxia, low levels of the protein frataxin result in progressive damage to the nervous system and loss of muscle function. Research in tissues derived from patients
Formulation of Sanofi Pasteur's Fluzone vaccine with Vaxfectin, also allowed a nearly 10-fold reduction in vaccine dose while generating equivalent or better antibody responses compared with an unformulated